How can the CSIRO help support Australia’s health research priorities?

FOOD & NUTRITION FLAGSHIP

Dr Lance Macaulay | CSIRO AIBL Science Leader25th September 2014

Informa

How can the CSIRO help support Australia’s health research priorities?

FOOD & NUTRITION FLAGSHIP

Dr Lance Macaulay | CSIRO AIBL Science Leader25th September 2014

Informa

Medical Research getting more from multidisciplinary collaboration with the CSIRO

3 |

64% of our people hold

university degrees over

2000 hold doctorates

over 500 hold masters

Who we are

Darwin

Alice Springs

Geraldton 2 sites

Atherton

Townsville2 sites

Rockhampton

Toowoomba

GattonMyall Vale

Narrabri

Mopra

Parkes

Griffith

BelmontGeelong

HobartSandy Bay

Wodonga

Newcastle

Armidale 2 sites

Perth3 sites

Adelaide3 sites Sydney 5 sites

Canberra 7 sites

Murchison

Cairns

Irymple

Melbourne 5 sites

Werribee 2 sites

Brisbane6 sites

Bribie Island

People 6035

Sites 55

Flagships 9

Budget $1B+

We develop 832 postgraduate research students with our university partners

DIGITAL PRODUCTIVITY ENERGY BIOSECURITY

National Research Flagships

4 |

OCEANS AND ATMOSPHERE

FOOD AND NUTRITION

AGRICULTURE

MINERAL RESOURCESMANUFACTURING

LAND AND WATER

informa

“Our Agriculture Flagship is helping Australian farmers and industry improve productivity and sustainability across the agriculture sector”

“We help to protect the health of our farming sector, environment and people by assembling the strongest multidisciplinary research teams available to tackle major national and international biosecurity challenges”

“Our science is used to make a positive impact on the future of innovation in Australian food, health and bio-based industries, and provide significant benefits to humanity through addressing key health challenges”

Agriculture, Food and Health

5 |

BIOSECURITY

FOOD AND NUTRITION

AGRICULTURE

informa

Manufacturing and Productivity

“By 2025 we aim to create $4 billion per annum in added value for the Australian economy by developing and delivering more efficient and innovative services that improve people’s wellbeing and prosperity”

“The Manufacturing Flagship is developing cleaner advanced materials and technologies to enable manufacturers to secure a competitive and sustainable future which contributes strongly to national productivity, economic growth and societal wellbeing”MANUFACTURING

DIGITAL PRODUCTIVITY

6 | informa

Our track record: top inventions

4. EXTENDED WEAR CONTACTS

2. POLYMER BANKNOTES

3. RELENZA FLU ANTIVIRAL

1. Fast WLANWireless Local Area Network

5. AEROGARD 6. TOTAL WELLBEING DIET

7. RAFT POLYMERISATION

8. BARLEYMAX 9. SELF TWISTING YARN

10. SOFTLY WASHING LIQUID

informa7 |

Working with CSIRO

8 | informa

Our Alliance engagement modelLong term, strategic relationships are mutually beneficial

Key Principles• Shared strategic priorities, objectives and IP principles• Common approach to relationship management• Mutual commitment to funding research• Coordinated project management and planning• Collective opportunity pipeline for prospects• Uniform engagement processes and practices

9 | informa

The CSIRO Flagship Collaboration Fund

informa

1. Help solve specific science problems2. Develop expertise within and outside CSIRO3. Build collaborative partnerships

Partners

10 |

ResearchClusters

Visiting Fellows PhDScholarships

ResearchProjects

informa

FCF Disbursements and Commitments ($M)

2008-09 2009-10 2010-11 2011-12 2012-13 2013-140.00

20.00

40.00

60.00

80.00

100.00

120.00

140.00

14.00 16.70 17.20 17.10 17.00 14.20

88.0096.00

108.00

121.00 124.00

133.30

Funds disbursedFunds committed

Financial Year

Mill

ion$

Health 17%

11 |

informa

Research Projects$77M

• Ngara• AIBL2• Health Diagnostics• Plant Breeding• eReefs• GEAI• Energy Waste• Stem Cell Biology• RAFT for Biomedical• Early Nutrition• Adaptation to Climate

Change• Renewable Chemicals• Solar Cells• Aero Engine• Big Data• Forests for the Future• Distal Footprint

Research Infrastructure

• Resources Sciences Precinct (Perth, WA)

• Manufacturing & Materials Sciences Precinct (Clayton, VIC)

• Natural Sciences Precinct (Canberra, ACT)

• Eco-Sciences Precinct (Brisbane, QLD)

• Health Sciences Precinct (Parkville, VIC)

• Information, Communication & Services Sciences Precinct (Sydney, NSW)

Promotion of Science

• CSIRO Macquarie University Chair in Wireless Communication

• John Stocker Postdoctoral Fellowships

• John Stocker Postgraduate Scholarships

• John O’Sullivan Postgraduate Scholarship

• SIEF Undergraduate Degree Scholarships

• SIEF-Australian Academy of Science Fellowships to the Lindau Nobel Laureate Meetings

Special Research Program

• Synchrotron Science

• ASKAP

SIEF Portfolio $150M invigorated by CSIRO Investment from WIFI.

Italics – completed RP; Potential RI activities

12 |

AIBL

Memory Complainers

Mild Cognitive Impairment

Alzheimer’s Disease

Neuropsychological assessment

Neuro-imaging

Biomarkers

Diet and Lifestyle (Intervention)

1,400 participants

60+ years old

Vascular

Health informatics

Healthy Controls

AIBL has become a world leading longitudinal cohort study of healthy aging specifically focussed on early detection, rate of progression, and preventative measures for Alzheimer’s disease.

13 | informa

*Total active participants at each time point including non-AD dementia. ¤63 participants left to screen for 54 months (Feb 2013).(NMC) Non-Memory Complainer, (SMC) Subjective-Memory Complainer, (MCI) Mild Cognitive Impairment, (AD) Alzheimer’s disease, PDD (Parkinson’s Disease Dementia),

VDM (Vascular Dementia), MCI-X (Mild Cognitive Impairment non-AD related).

AIBL: Longitudinal cohort: Baseline to 54 months.

Baseline(1,112)

18 month (972)*

36 month (824)*

(33) (29) (50)(29)

(97) (114) (7) (13)(4) (1) (3) (32)

(39)(41) (62)(26)

(1)(78) (62) (4)(5) (14) (1) (16)

(220) (254) (161)

(212) (241)

(65)

(35) (134)

(14)

(50) (72) (7) (4) (19) (1) (6)(202) (207) (27) (68)

Non-return:74

Deceased:NMC 2SMC 1MCI 1AD 27VDM 1

Non-AD dementia:MCI-X 2VDM 2

54 month¤

(676)*

255 NMC 290 SMC 51 MCI 76 AD

(2)

ApoE4 carrier

107 (28.8%)ApoE4 carrier97 (24.5%)

ApoE4 carrier66 (49.6%)

ApoE4 carrier132 (62.6%)

ApoE4 carrier90 (28.4%)

ApoE4 carrier94 (25.1%)

ApoE4 carrier32 (39.0%)

ApoE4 carrier136 (69.0%)

ApoE4 carrier82 (27.2%)

ApoE4 carrier80 (25.8%)

ApoE4 carrier24 (43.6%)

ApoE4 carrier106 (68.8%)

ApoE4 carrier64 (25.1%)

ApoE4 carrier74 (25.5%)

ApoE4 carrier19 (37.3%)

ApoE4 carrier52 (68.4%)

396 SMC 133 MCI 211 AD

Non-return:112

Deceased:NMC 2SMC 4MCI 5AD 17

Non-AD dementia:PDD 1

Non-return:120

Deceased:NMC 3SMC 3MCI 4AD 34

Non-AD dementia:PDD 1

MCI-X 1VDM 3

Returned at 36 months:NMC 11

SMC 1MCI 1AD 3

Returned at 54 months:NMC 1 SMC 4MCI 1AD 1

372 NMC

317 NMC 375 SMC 82 MCI 197 AD

(20) (62)(10)

301 NMC 309 SMC 55 MCI 154 AD

Biomarkers =Early Detection

Rate of progression

Prevention and Treatment =

Diet and LifestyleFunctional foods

Therapeutics

A

CB

Dx

y

z

AD

AB AC

Science challenges

15 | Teijin | Lance Macaulay

Slow onset of Alzheimer’s confirmed

First time the hypothesized slow onset of Alzheimer's disease has been confirmed by longitudinal observation

~17 years before onset of dementia

Beta-amyloid levels become abnormal and can be detected on amyloid PET scan

~4 years before onset of dementia

Hippocampal atrophy can be detected on an MRI scan

~3 years before onset of dementia

Memory impairment can be detected on neuropsychological tests

The natural history of sporadic Alzheimer’s disease: dynamics of A-Beta amyloid deposition, neurodegeneration and cognitive decline. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Macaulay SL, Martins R, Maruff P, Ames D, Rowe C, Masters CL, Lancet Neurology 12;357-67, 2013

16 |

AIBL Progress

2006 2007 2008 2009 2010 2011 2012 2013

200818 month data

collection

992 in cohort

Amyloid imaged 288

201036 month data

collection

824 in cohort

201254 month data

collection

676 in cohort+ enrichment

2006AIBL launched

1,112 in cohort

2010AIBL 2

launched with SIEF funding

$5.15M/3yr

2013~10% of cohort

transitioned to Alzheimer’s

disease

$1.2M in foreign investment (2006 – 2009)

11 external EOI

>$10M in foreign investment and $2.9M National additional to

SIEF to date

>35external EOI

>650 group accessed via LONI

2011 Enrichment Cohort 237

CSFcollection

.

AIBL participates in

ADNI

Imaging increased to 750

17 informa

$3M Flagship Collaboration fund

$1M additional FCF

AIBL Achievements

2006 2007 2008 2009 2010 2011 2012 2013 2014

2006AIBL launched

2013~10% of cohort transitioned to

Alzheimer’s disease

Natural History of AD

>60 publications

Prognostic blood biomarker Patent

Retinal biomarker patent

Amyloid imaging

results from AIBL

Diagnostic blood

biomarker patent

AIBL hosted world consensus

standardisation meeting RASAD

and LAPAD lifestyle satellite.

AIBL participates in

ADNI

Dynamics of amyloid PET and brain volumetric

changes.

Automated image analysis patent. Retinal

biomarker patent

MeDi diet and Physical activity

protective.

Papers 2 9 10 16 25 29 Total>100 pubs18

.

2010AIBL 2 launched with

SIEF funding

9 PhD students completed 12 progressing

8 Masters(2006 – 2012)

Foundation data for new diagnostic criteria for prodromal and preclinical AD

18 informa

>100 publications

>650 groups granted access via LONI

Opportunity• Initially as a tool to prescreen at risk people for drug trials prior to

PET or CSF screening.• Long term. Primary detection low cost blood population screen for

early detection prior to PET confirmation. Like cholesterol for heart disease.

• At a GP might deliver with Computerised cognitive test. GP delivered with, or after, primary screen. (Cogstate)

• More extensive cognitive battery for early detection and confirm disease status with PET/CSF.( All PET amyloid agents trialed in AIBL, Avid (florbetapir), GE (flutametamol), Piramal (florbetaben).

• Rate of progression prognostic panel to define treatment. • Interventions

LifestyleMediterranean diet and physicalactivity

TherapeuticDrug trials

Omega fund 2013

Bringing our research worlds together

20 |

Early Detection = Biomarkers

Our Focus: Early Detection and Prevention

Prevention =

Alzheimer’s Disease Stroke

Diet and Lifestyle

Functional Foods

Therapeutics EXTEND

A

CB

Dx

y

z

AD

AB A

C

ASPREE

21 | informa

CSIRO National Biologics Facility (CSIRO node)

informa

• established under NCRIS with subsequent support from SSI

• a unique ~$16M facility with expert capabilities and dedicated staff

• ISO9001 accredited to provide protein for in vivo studies

• over 150 research “partners” from universities to industry

• variety of biological hosts (bacterial, insect, mammalian, yeast)

• downstream purification, processing, modification etc.

Strategic Alliance – Circadian TechnologiesImpact from Science

Since 2006, we have worked with Vegenics (a subsidiary of the Australian biotechnology company, Circadian Technologies) to accelerate their therapeutic research program for the control of angiogenesis in oncology and eye disease. This has drawn on our skills in molecular, cellular and fermentation biology, protein engineering and biophysical characterisation of proteins. Recent company milestones include:

• initiation of phase I clinical trials for VGX-100 for the treatment of solid tumours

• new patents around the diagnostic application of VGX-300, a receptor fusion protein

• the marketing of novel, highly potent recombinant isoforms of VEGF-C and VEGF-D

23 | informa

informa

• Researchers have identified new genes that show changes in the blood of people with bowel cancer.

• This discovery underpins a new blood test that can be used as a screening tool for people who cannot, or will not, use the faecal immunochemical blood test (FIBT).

• These exciting results are the result of over five years of scientific collaboration.

Positive impact: Colorectal cancer screening test

24 |

informa

Digital connectivity is a game-changer

25 |

Transition from physical to virtual

Physical Connectedness

Care needs, physical mobility reduction

Virtual Connectedness

informa

informa

Psychology & Perception

Smarter Safer Homes

ICT in Health & Biomedical Engineering

Sensor NetworksUser Interface design & Interaction

27 |

Smarter Safer HomesBringing home the virtual world

Platform:• Consumer-driven• Daily living• Community and family• Sensors in the home

informa28 |

informa29 |

informa

Evaluation in NBN Tele-eye Care systemCollaboration with DoHA - AU$2 million project in WA and QLD

Dr.Grader30 |

Responding To New Science Frontiers

31 |

HEALTHCARE AND RESEARCH TRENDS

PREVENTION

PERSONALISATION

NEW DELIVERY MODES

TECHNOLOGY ANDINNOVATION

GENOMICS• BIOINFORMATICS• GENOMICS• METABOLOMICS• EPIGENOMICS• BIOMARKERS OF DISEASE

ICT PLATFORMS• QUANTIFIED SELF• DIAGNOSTIC

SENSORS• MOBILE HEALTH

Lynne Cobiac

informa

Great expectations...Personalisation of health and medicine to focus on well being and prevention

32 |

PERSONAL HEALTH

DIAGNOSTICS

PERSONAL LIFESTYLE

REQUIREMENTS

LIFESTYLES TAILORED TO

THE INDIVIDUAL

=IDENTIFIES

informa

Key Challenge:

A Scientifically Valid Personalized Predictive Health Risk Profile

33 |

The global challenge

FOOD AND NUTRITION FLAGSHIP

Thank youFood and Nutrition FlagshipDr Lance MacaulayCSIRO AIBL Science LeaderGroup Leader Personalised HealthLance.Macaulay@csiro.au